Biotech Firm AIRNA Enters Global Research Consortium to Advance RNA Editing Therapies for Genetic Lung Disease

AIRNA partners with C-Path’s AATD consortium to accelerate RNA-editing treatments and streamline regulatory pathways for rare genetic lung and liver diseases.

By: AXL Media

Published: Apr 23, 2026, 6:04 AM EDT

Source: Information for this report was sourced from EurekAlert!

Strategic Alliance for Next Generation Genetic Medicine

The Critical Path Institute (C-Path) has expanded its collaborative efforts by welcoming AIRNA as a strategic industry partner within its Alpha-1 Antitrypsin Deficiency (AATD) Consortium. This move coincides with the initiation of AIRNA’s RepAIR1 global clinical study, marking a significant step in applying RNA-editing expertise to a complex genetic condition. By joining established pharmaceutical leaders such as Sanofi, Takeda, and CSL Behring, AIRNA intends to contribute to the collective development of regulatory-endorsed solutions for patients. According to C-Path officials, the integration of these diverse scientific perspectives is essential for navigating the evolving landscape of genetic therapeutics and ensuring that innovative treatments meet rigorous safety and efficacy standards.

Navigating Complex Regulatory and Clinical Hurdles

As therapeutic approaches for AATD transition from symptom management to addressing genetic mutations, the industry faces unprecedented challenges regarding trial endpoints and biomarker validation. The consortium serves as a precompetitive public-private partnership where academic researchers and industry stakeholders collaborate to solve these technical bottlenecks. According to Collin Hovinga, Vice President of Rare/Orphan and Pediatric Disease Programs at C-Path, the addition of scientific ingenuity like RNA editing is vital for accelerating the pace of drug development. By working together, the members aim to establish standardized clinical trial designs that can be endorsed by regulatory agencies, ultimately reducing the time required for new therapies to reach the market.

Precision RNA Correction Without Genomic Alteration

At the center of this partnership is AIRNA’s proprietary lead program, AIR-001, which has recently secured Orphan Drug Designation from the U.S. Food and Drug Administration. Unlike traditional gene editing that permanently modifies DNA, AIRNA’s approach focuses on correcting disease-causing mutations at the RNA level. This method is designed to provide the precision of genetic medicine while maintaining a flexible, reversible, and repeatable treatment framework delivered via subcutaneous injection. According to Dr. Jacob S. Elkins, Chief Medical Officer of AIRNA, this "best-in-class" potential therapy represents a shift toward functio...